GQ1005 / GeneQuantum Healthcare 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
2 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
GQ1005 / GeneQuantum Healthcare
GQ1005-102, CTR20222855: A first-in-human, multicenter, open-label, dose-escalation and expansion Phase I clinical study of GQ1005 in subjects with HER2-expressing advanced solid tumors

Recruiting
1
30
China
GQ1005 - GeneQuantum Healthcare
Qide Pharmaceutical Technology (Suzhou) Co., Ltd
HER2-expressing advanced solid tumors
 
 
NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25

Download Options